A
Allogene Therapeutics
Biotech & Life Sciences · San Francisco, United States · Founded 2018 · IPO 2018
Global footprint
Where Allogene Therapeutics has talent and traffic
team presence
across markets
Talent graph
The shape of Allogene Therapeutics's talent
Dealroom maps Allogene Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.
Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.
Patent intelligence
$78M patent portfolio · 67 active families
Where Allogene Therapeutics concentrates vs peers
Each axis is a top-10 topic across Allogene Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Capital deployed
Allogene Therapeutics's 3 investments and acquisitions.
Every disclosed deal where Allogene Therapeutics appeared as a backer or acquirer, 2021–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Allogene Therapeutics's capital deployment.
Where the deals concentrate by sector, stage, and decade.
01 · Deployment strategy vs peers
Where Allogene Therapeutics deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
02 · Portfolio market map
Allogene Therapeutics's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
What the market is saying about Allogene Therapeutics
An AI-synthesized read of the highest-engagement posts about Allogene Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Allogene Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.